Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC

NCT05485896 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Pembrolizumab plus Lenvatinib

Sponsor

Tianjin Medical University Second Hospital